Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    gastroenterology

    Cholangiocarcinoma

    Also known as: Bile duct cancer, Biliary tract carcinoma, Intrahepatic cholangiocarcinoma, Perihilar cholangiocarcinoma, Distal cholangiocarcinoma

    Cholangiocarcinoma is a malignant neoplasm of the biliary tract, classified as intrahepatic or extrahepatic. Diagnosis, staging, and therapeutic interventions—including biliary decompression, surgical resection, and systemic oncology regimens—necessitate specialist hepatobiliary and oncological management. Traditional Chinese Medicine (TCM) may be considered only as coordinated adjunctive symptom support, not tumour treatment. Current evidence lacks controlled trials for acupuncture in this context. A single case report concerning postoperative cupping is insufficient to establish efficacy or safety; similarly, a small retrospective study on integrative herbal medicine indicates associations rather than definitive evidence of survival benefit. Research into ferroptosis mechanisms and retrospective imaging prediction do not establish patient benefit from TCM. The specified patterns represent traditional diagnostic frameworks for symptom clusters rather than validated oncology stages or treatment protocols.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Maintain a precise log of pain intensity, nausea, pruritus, body temperature, and alterations in urinary or faecal pigmentation for clinical review.
    • •Choose tolerable small meals and obtain early dietetic support if intake or weight declines.
    • •Balance periods of rest with light physical activity agreed with the oncology team; avoid pushing through marked fatigue or dizziness.
    • •Cessation of tobacco and alcohol consumption is advised; all supplements, botanical teas, and herbal products must be disclosed to the treating physicians prior to any modification of the therapeutic regimen.

    Cautions & Contraindications

    See sources
    • •Do not needle infected skin, unhealed incisions or areas around biliary drains and vascular access devices. Do not offer blood-letting cupping for wound infection: source [2] is one case and cannot establish safety or justify routine use.[]
    • •Defer invasive adjunctive treatment during fever or suspected infection; obtain oncology clearance where neutropenia, thrombocytopenia, anticoagulation or poor healing creates risk. These are general procedural precautions, not thresholds established by the case report.[]
    • •Do not extrapolate the retrospective herbal association in source [4] to these formulas, prescribe them as anticancer treatment, or substitute them for adjuvant therapy. The supplied study does not establish their interaction safety, pregnancy safety or suitability in hepatic impairment.[]

    When to reassess or seek care again

    See sources

    If the oncology team agrees to a symptom-focused trial, document baseline 0–10 pain, nausea, fatigue and dryness scores, oral intake, bowel frequency and weight trend. Review after 1–2 weeks or 2–3 visits. Stop or revise adjunctive care if there is no meaningful agreed symptom improvement, any adverse effect or interference with oncology treatment. Escalate worsening jaundice, declining intake or new progressive pain promptly; infection or sepsis features require immediate assessment. Oncology imaging and laboratory surveillance remain unchanged.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. Frontiers in cell and developmental biology · 2026
    2. Frontiers in medicine · 2026
    3. European journal of radiology · 2026
    4. Journal of molecular histology · 2026

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.